...
首页> 外文期刊>Journal of managed care pharmacy : >Development and delivery of a quality improvement program to reduce antipsychotic polytherapy.
【24h】

Development and delivery of a quality improvement program to reduce antipsychotic polytherapy.

机译:制定并实施质量改进计划,以减少抗精神病药物的综合治疗。

获取原文
获取原文并翻译 | 示例
           

摘要

appropriate in limited circumstances (e.g., during a brief "cross-titration" period when switching medications), its increasing prevalence indicates use beyond this limited scope. Despite absence of support in the medical literature and higher costs, antipsychotic polytherapy is common in the treatment of schizophrenia and related disorders. The highest utilization of antipsychotic polytherapy occurs on psychiatric inpatient units, and in 2008, the Joint Commission released the first set of 7 hospital-based inpatient psychiatric services (HBIPS) core measures, 2 of which assess antipsychotic polytherapy at time of discharge. OBJECTIVE: To describe the effect on antipsychotic polytherapy at time of discharge of a 2-part quality improvement program composed of educational seminars and prescriber-specific feedback provided to 11 psychiatrists in 4 acute inpatient psychiatric units in 2 hospitals. METHODS: In a regional academic health care system, we determined the prevalence of antipsychotic monotherapy and polytherapy at time of discharge for all patients discharged on standing antipsychotic medications during 3 periods: (a) a 3-month baseline period (August 2006 through October 2006); (b) in July 2007, after delivery of 4 educational luncheon seminars to 11 psychiatrists from November 2006 through June 2007; and (c) in June 2008, following the provision of monthly prescriber-specific audit feedback from August 2007 through June 2008. To prepare nurses for the change and address possible safety concerns, an educational module was delivered to the psychiatric nursing staff at "best practice" day lectures held in the first quarter of 2007. General themes in the educational presentations included literature-based reviews of (a) safety and efficacy of antipsychotic polytherapy, (b) medical risks of antipsychotic medications, (c) specific versus nonspecific effects of these medications, and (d) effectiveness of first- versus second-generation antipsychotic medications. The prescriber-specific audit feedback was provided in paper form and masked the identity of the other prescribers. The chief of service reviewed audit feedback individually with each psychiatrist on a quarterly basis. The primary outcome measure was the percentage of patients prescribed 2 or more antipsychotics at discharge. A secondary outcome measure was the percentage of patients prescribed 3 or more antipsychotics at discharge. Differences in the primary outcome measure, comparing (a) July 2007 with the baseline period and (b) June 2008 with July 2007, were analyzed using Fisher's Exact tests. The Cochran-Armitage test for trend was used to assess the relationship between the primary outcome measure and the extent of the intervention, measured as the 3 time periods. For the secondary outcome measure, the Goodman-Kruskal gamma test for ordered categorical data was calculated to examine the association between the the proportion of patients receiving 1, 2, or 3 or more antipsychotics at discharge and the 3 time periods. RESULTS: The percentage of patients prescribed 2 or more antipsychotics at discharge declined from 33.9% at baseline (132 of 389 patients), to 21.8% after delivery of the educational modules (44 of 202 patients, P = 0.002), and to 12.2% after audit feedback (18 of 147 patients, P = 0.023; Cochran-Armitage test for trend P < 0.001). When antipsychotic use was classified as 1, 2, or 3 or more antipsychotic medications, more extensive intervention was associated with decreased combination use (Goodman- Kruskal gamma = 0.39, P < 0.001). In the baseline period, 5.9% of patients were prescribed 3 or more antipsychotics at discharge. Following completion of the educational and audit components, respectively, the proportion of patients prescribed 3 or more antipsychotics declined to 2.5% and then to 0.0%. CONCLUSION: Educational modules presented to psychiatrists and nurses in group settings were associated with a decrease in the rate of prescribing 2 or mo
机译:如果在有限的情况下(例如在更换药物时短暂的“交叉滴定”期间)适当使用,则其流行率不断增加,表明该药物的使用超出了此有限的范围。尽管在医学文献中缺乏支持并且费用较高,但是抗精神病药物多疗法在精神分裂症和相关疾病的治疗中是常见的。抗精神病药物综合疗法的利用率最高,发生在精神科住院患者中,2008年,联合委员会发布了第一套7项基于医院的住院精神病服务(HBIPS)核心措施,其中两项评估出院时的抗精神病药物综合疗法。目的:描述分两部分的质量改进计划对抗精神病药物多联疗法的影响,该计划包括教育研讨会和针对2家医院的4个急性住院精神病学部门的11位精神科医生提供的特定处方反馈。方法:在一个地区性的学术医疗体系中,我们确定了在以下三个时期内所有使用常规抗精神病药物出院的患者出院时抗精神病药物单药治疗和多药治疗的患病率:(a)3个月的基线期(2006年8月至2006年10月) ); (b)在2006年11月至2007年6月为11名精神科医生举办了4次教育午餐会之后,于2007年7月; (c)在2007年8月至2008年6月之间,每月提供针对特定处方者的审核反馈意见之后。2008年6月。为使护士为这种变化做准备并解决可能的安全隐患,我们以最佳的方式向精神科护理人员提供了教育模块2007年第一季度举行的“实践”日讲座。教育演讲的一般主题包括基于文献的综述,涉及(a)抗精神病药多联疗法的安全性和有效性,(b)抗精神病药的医疗风险,(c)特异性与非特异性作用这些药物,以及(d)第一代与第二代抗精神病药物的有效性。特定于处方者的审核反馈以纸质形式提供,并且掩盖了其他处方者的身份。服务负责人每季度与每位精神科医生分别审查审核反馈。主要结局指标是出院时开具2种或2种以上抗精神病药的患者百分比。次要结果指标是出院时开具3种或以上抗精神病药的患者百分比。使用Fisher精确检验分析了主要结局指标的差异,将(a)2007年7月与基线期进行了比较,以及(b)2008年6月与2007年7月进行了比较。趋势的Cochran-Armitage检验用于评估主要结果指标与干预程度之间的关系,以3个时间段衡量。对于次要结局指标,计算有序分类数据的Goodman-Kruskal伽玛检验,以检查出院时接受1种,2种或3种或更多种抗精神病药的患者比例与3个时间段之间的关联。结果:出院时开具2种或2种以上抗精神病药的患者比例从基线时的33.9%(389例患者中的132例)下降到分娩教育模块后的21.8%(202例患者中的44例,P = 0.002)和12.2%审核反馈后(147名患者中的18名,P = 0.023; Cochran-Armitage检验趋势P <0.001)。当将抗精神病药物分类为1种,2种或3种或3种以上抗精神病药物时,更广泛的干预与联合用药减少有关(Goodman-Kruskal gamma = 0.39,P <0.001)。在基线期,出院时有5.9%的患者开了3种或以上抗精神病药。分别完成教育和审计工作后,开具3种或3种以上抗精神病药的患者比例下降到2.5%,然后下降到0.0%。结论:在小组环境中向精神科医生和护士提供的教育模块与开处方2或3的比例降低有关

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号